阿莫西林-克拉维酸钾序贯治疗小儿急性下呼吸道感染的成本-效果评价

Cost-effect analysis of amoxicillin-elavulanate potassium sequential therapy in treating children with acute lower respiratory tract infection

目的探讨阿莫西林-克拉维酸钾序贯疗法治疗小儿下呼吸遭感染的有效性与药物经济学意义。方法对180例急性下呼吸道感染患儿按入院先后顺序随机分为观察组与对照组,每组90例。观察组先给予阿莫西林-克拉维酸钾注射液100 mg/kg.d静脉滴注,待退热或血常规恢复正常后改为阿莫西林克-拉维酸钾片剂50 mg/kg.d口服,直至症状消失;对照组给予阿莫西林-克拉维酸钾注射液100 mg/kg.d静脉滴注,直至症状消失。比较两组的疗效并运用药物经济学进行评价。结果两组比较痊愈率及有效率无显著差异(P>0.05);治疗组平均总费用(535.0元)明显低于对照组(750.0元),观察组平均住院时间(8.5±1.5)d明显少于对照组(11.5±3.5)d。结论阿莫西林-克拉维酸钾序贯治疗小儿急性下呼吸道感染临床疗效可靠,费用低,治疗成本效果较优,可在临床推广应用。

Objective To evaluate the efficacy and pharmcoeconomics of amoxicillin-elavulanate potassium sequential therapy in treating children with acute lower respiratory tract infection（ALRI）.Methods By order of admission,180 cases of children with ALRI has randomly divided into observation group and control group（n=90 cases）.Observation group was first given amoxicillin-clavulanate potassium injection 100 mg/kg·d intravenous infusion,fever or blood in the return to normal after giving amoxicillin-clavulanate potassium tablets 50 mg/kg·d orally,until the symptoms disappear.control group was given amoxicillin-clavulanate potassium injection 100 mg/kg·d intravenous infusion until the symptoms disappear.The two groups were compared efficacy and use of pharmacoeconomic evaluation.Results The cure rate between the two groups and the efficiency was no significant difference（P〉0.05）;average total cost of the treatment group（1922.4yuan） was significantly lower than the control group（2956.5 yuan） to observe the group,the average length of stay（8.5±1.5）d significantly less than the control group（11.5±3.5）d.Conclusion Sequential treatment of children with amoxicillin-clavulanate potassium clinical efficacy of children with acute lower respiratory tract infection is reliable and economical.